Significance Statement

Currently, the clinical presentation, optimal management strategy, and outcomes for patients with kidney transplants who develop COVID-19 infection remain unknown. The description of our cohort represents the first cohort of patients with kidney transplants and COVID-19 infection and includes clinical features, markers of inflammation, and a strategy for management that includes both immunosuppression reduction and the use of adjuvant therapy, including hydroxychloroquine, azithromycin, and tocilizumab. This approach appears to have resulted in favorable outcomes in our cohort of hospitalized kidney transplant patients and provides an effective treatment strategy for the management of these patients